Paragon Therapeutics appoints first chief executive

US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact.

“I have been impressed and inspired by the Paragon’s mission, scientific excellence, and sense of urgency to advance important novel treatments to patients and I am excited to be working with such a dedicated and accomplished team to maximize the potential of Paragon’s technology and rapidly progress our pipeline,” said Ms High.

“Susanna brings the optimal set of expertise to further Paragon’s mission,” said Evan Thompson, chief operating officer at Paragon, adding: “An experienced and innovative leader, her industry acumen and drug development expertise will ensure we continue to fuel the development of novel biologics with the power to improve lives.”